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Abstract—This paper presents a control strategy for blood glu-
cose (BG) level regulation in type 1 diabetic patients. To design
the controller, model-based predictive control scheme has been ap-
plied to a newly developed diabetic patient model. The controller
is provided with a feedforward loop to improve meal compensa-
tion, a gain-scheduling scheme to account for different BG lev-
els, and an asymmetric cost function to reduce hypoglycemic risk.
A simulation environment that has been approved for testing of
artificial pancreas control algorithms has been used to test the
controller. The simulation results show a good controller perfor-
mance in fasting conditions and meal disturbance rejection, and
robustness against model–patient mismatch and errors in meal
estimation.
Index Terms—Gain scheduling (GS), model predictive control
(MPC), type 1 diabetes mellitus (T1DM).
I. INTRODUCTION
D IABETES mellitus is a disease characterized by pancreasinability to regulate blood glucose (BG) levels. For glu-
cose to be transported into cells, insulin, which is a hormone pro-
duced by the pancreas, is needed. If the delivered insulin is less
than required or no insulin is produced at all, BG concentrations
elevate to abnormal levels. As a result, the human body loses
its most important energy source, and the accumulated BG be-
comes toxic to several tissues and organs if not treated. This inef-
fective/insufficient or no insulin secretion is known as diabetes.
In type 1 diabetes (T1DM), the immune system attacks and
destroys the insulin producing β-cells in the pancreas. Thus, for
T1DM patients to maintain glucose level close to normal, they
have to take exogenous insulin injections or infusion daily. Con-
ventional therapy depends mainly on insulin injections, taken
three or four times per day to replace the insulin function. If
glucose level is not controlled carefully within a tight range,
long-term complications, ketoacidosis, and hypoglycemic coma
can occur, with the latter being more life-threatening. Beside the
insulin problem, glucose counter-regulation system is severely
impaired in T1DM; glucagon secretion in response to hypo-
glycemia is highly decreased with the increasing endogenous
insulin deficiency.
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Since 1970s, the idea of closed-loop artificial pancreas (AP)
has been addressed as the solution to replace the existing treat-
ment, and to improve the disease management (see [1] and [2]).
While no commercial AP is currently available, the compo-
nents of the AP, i.e., the continuous subcutaneous (s.c.) insulin
infusion (CSII) pump, and the continuous glucose monitoring
(CGM), are being used in open-loop setup. Although the sensors
and pumps systems still have their limitations, their use has re-
sulted in better clinical outcomes over conventional therapy [4].
A wide spectrum of control algorithms for closing the loop have
been proposed (see reviews by Baquette et al. [2] and Takahashi
et al. [3]). However, inter- and intrapatients variability in insulin
sensitivity, variability in patient condition, mismatch between
the models used to develop the control and real patients, as well
as the limitations of the s.c. route used for glucose sensing and
insulin delivery makes it very difficult to find a general and a
reliable solution to the highly nonlinear problem of glycemic
control and insulin therapy optimization.
This paper presents a model predictive control (MPC) algo-
rithm for the BG control problem in T1DM, used with a newly
developed glucose–insulin model. The proposed MPC scheme
employs the following:
1) feedforward action, for the compensation of meal effect
by anticipatory control action that prevents large hyper-
glycemic peaks;
2) hard constraints on insulin input, for patient’s safety con-
cerns and pump hardware specifications;
3) output constraints are implemented with unequal degrees
of softness to penalize the hypoglycemic events more ag-
gressively than hyperglycemic events, since hypoglycemia
is more life threatening;
4) a gain-scheduling (GS) technique assigns specific insulin
dosing profile for each glycemic range.
The designed controller has been evaluated in silico; a simu-
lation environment with virtual diabetic subjects has been used
to test and tune the controller.
This paper is structured as follows. Section II briefly de-
scribes the patient model and the simulation environment; the
idea of the developed closed-loop algorithm, composed of MPC
with feedforward control action and GS scheme, is given in
Section III; the results obtained in the simulation scenarios are
presented and discussed in Section IV; and finally, conclusions
are drawn in Section V.
II. SIMULATION MODEL
Preclinical testing trial is a critical step to evaluate the per-
formance and robustness of closed-loop control algorithms. Re-
cently, in silico environments are being increasingly used for
0018-9294/$26.00 © 2009 IEEE
ABU-RMILEH AND GARCIA-GABIN: GAIN-SCHEDULING MODEL PREDICTIVE CONTROLLER FOR BLOOD GLUCOSE CONTROL IN TYPE 1 DIABETES 2479
controllers testing [7], [14], and have shown ability to replace
the animals’ trials step in the development of clinical tools,
while providing realistic results and covering a wider range of
the variability observed among diabetic population [7]. These
environments have as main building block a model that de-
scribes the T1DM patients (virtual subject). Many models have
been investigated for in silico studies; these models range from
simple linear models (e.g., Ackerman model) to nonlinear mod-
els (Bergman, and De Gaetano models) and comprehensive
mathematical models (e.g., Cobelli, Sorensen, Hovorka, and
Dalla Man models). For a detailed review on available models,
see [15].
The meal model developed by Man et al. [8], [9] consists
of a glucose and insulin compartments network linked by the
control of glucose on insulin secretion, and by insulin on glucose
utilization and endogenous production. The model has been
modified to adapt for T1DM subjects and insulin exogenous
infusion [10]. The model has been implemented in a simulation
environment (UVa T1DM simulator) that has been accepted by
the Food and Drug Administration (FDA) as a substitute for
animals’ trial in preclinical testing of closed-loop AP control
algorithms [7]. In addition to the patient model, the simulator
incorporates two other models: a sensor-related errors model to
account for sensor noise and measurements’ errors [7], [11], and
a model for the s.c. insulin pump. In this paper, the controller
has been tested with ten adults available in the training version
of the simulator.
III. CONTROLLER DESIGN
A. Model Predictive Control (MPC)
MPC is a control strategy that has considerably developed
over the past few years. MPC is fundamentally based on dis-
crete model of the system to be controlled. A model is used to
predict the future system outputs, based on the past and current
values, and on the proposed future control actions. These actions
are calculated by optimizing a cost function where the future
tracking error is considered and the system constraints, if any.
MPC employs a receding horizon strategy—repeated displace-
ment of the time horizon, while applying only the first control
signal in the calculated sequence at each time step, with the rest
of the sequence discarded.
MPC has many features that make it a competitive candidate
for the BG control problem:
1) prediction property of MPC that allows for anticipatory
and careful insulin delivery;
2) it can be useful to overcome the physiological delays as-
sociated with the s.c. route [18];
3) compensation for dead time, which exists in glucose prob-
lem;
4) feedforward control action to compensate for known
sources of disturbance, such as meal intake;
5) constraints handling on system inputs and outputs.
MPC algorithms have been used in a number of AP publi-
cations, where the applicability of such controllers was demon-
strated [19]–[23].
To apply a linear MPC, a good linearized version “approxi-
mation” of the nonlinear model proposed in [8] and [10] should
be obtained. In this paper, the state-space approach has been
chosen to formulate the MPC problem, since it can be easily ex-
tended to multivariable and nonlinear systems [17]. An average
patient model (a patient whose parameters are the averages of
the ten adults’ parameters) has been obtained, and the nonlinear
model is linearized at three different operating points (65, 120,
and 220 mg/dL) in three glycemic ranges (<70, 70–180, and
>180 mg/dL), and the obtained models are descretized (with
Ts = 5 min), and used to design three linear MPC’s. The dis-
crete linearized state-space models obtained from the nonlinear
patient’s model can be written as
xk+1 = Axk + Buuk + Bvvk + Edk
yk = Cxk + Dvvk + Dddk (1)
where An×n , Bn×1 , En×1 , C1×n , and D1×1 are the matrices of
the linearized model with n being the system order (n = 13), xk
(deviation from linearization point) is the model states vector
(13 states), uk (deviation from linearization point) is the insulin
input in picomols per minute per kilogram, and converted to
units per hour later in this paper for more convenient represen-
tation (1u = 6000 pmol), vk is the meal intake disturbance in
milligrams, dk is the sensor errors in milligrams per deciliter,
and yk is the measured glucose level in milligrams per deciliter
(s.c. glucose plus sensor errors). The errors dk are modeled as
integrated white noise in order to approximate the sensor errors
presented in the UVa simulator (for errors model, see [11]).
The control action uk is governed by optimizing a quadratic
cost function, penalizing predicted output deviations and control
signal along some prediction horizons. The used cost function
has the form
min
∆u


J =
Hp∑
j=1
‖wy (yˆ(k + j|k)− r(k + j))‖2
+
Hu∑
j=1
∥∥w∆u∆u(k + j|k)∥∥2 + qε2


s.t.
umin ≤ uk ≤ umax
∆umin ≤ ∆uk ≤ ∆umax
ymin − εVmin ≤ yˆk ≤ ymax + εVmax
(2)
where yˆ(k + j|k) is the j-step prediction of the output on data
up to instant k, r(k + j) is the reference glucose level, ∆u is
the input increment, Hp and Hu are the prediction and control
horizons, respectively, w∆u and wy are weights on the control
action increments and the error between y(k) and r(k), respec-
tively, ε is a slack variable used for output constraints softening,
q is weight on the slack variable ε, umin/max , ∆umin/max , and
ymin/max are the constraints imposed on the input, input in-
crements, and output, respectively, and Vmin and Vmax are the
relaxation variables.
Since hard output constraints may cause infeasibility in the
optimization problem (e.g., because of unpredicted disturbances
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or model mismatch), ε is defined for output constraints softening
[16]. The weight q on ε penalizes the violation of the constraints.
The larger the qε with respect to input and output weights, the
more the constraint violation is penalized. The cost function in
(2) is asymmetric; the lower and upper output constraints are
subjected to unequal relaxation bands, and therefore, the con-
straints have different levels of softness. The unequal softness
levels could be achieved by introducing the nonnegative relax-
ation variable Vmin and Vmax , which represent the concern for
relaxing the corresponding constraint; the larger the V, the softer
the constraint. The reason for such an asymmetry is to penalize
the hypoglycemic events more aggressively than hyperglycemic
events, since the former is more life-threatening. For the weights
w∆u and wy , the smaller w, the less important is the behavior
of the corresponding variable on the overall performance index.
B. GS Control (GSC)
GSC is a well-known technique for controlling nonlinear sys-
tems by linear controllers. For a successful employment, GSC
requires the identification of scheduling parameters that can be
used to select the suitable linear controller for each operating
range of the nonlinear system [26]. GSC overcomes the limita-
tions of the basic linear approximation approach, which is valid
only in a neighborhood of a single operating point. After identi-
fying one or more scheduling parameters, the nonlinear model is
linearized, and linear controllers for different operating ranges
can be designed. Then, the set of linear controllers is imple-
mented as a single controller whose parameters are changed by
monitoring the scheduling variables. GSC schemes show a per-
formance similar to that of nonlinear controllers applied to the
same problems, with computational load being smaller in the
GSC approach [27].
For the problem at hand, the GSC can be of vital importance
for many reasons. In healthy subjects, the level of insulin activ-
ity varies between different glycemic ranges, being dominant in
hyperglycemic range, in balance with glucagon action in normo-
glycemia and almost inactive in the hypoglycemic range where
glucagon is dominant. Also, it is proved that the insulin therapy
causes more degradation in the functionality of counterregula-
tory hormones that are working to correct the hypoglycemic
episodes induced by insulin overdose [24], and consequently,
results in higher possibility for hypoglycemic risk. Finally, con-
sidering the fact that hypoglycemia does not occur naturally in
diabetic patients, but can result from insulin therapy [25], the
control algorithm should avoid substituting one problem for an-
other. Therefore, different weights should be imposed on the
insulin dose depending on different BG ranges in order to deal
with the iatrogenic hypoglycemia that is considered to be the
main limiting factor in tight control of diabetes [24], [25].
A simplified diagram of the GS-MPC scheme is shown in
Fig. 1. As can be seen in the figure, the scheduling variable
used here is the output variable (i.e., measured glucose levels).
Three different regions have been defined corresponding to the
normo-, hyper-, and hypoglycemic ranges. The three linearized
models obtained in Section III-A have been used to design the
family of the MPC controllers. The GS is used to select between
Fig. 1. MPC with GS, the CGM output is delivered to MPC as feedback loop,
and to GS to select the controller to be used. Also, MPC receives the set-point
value r(k) and meal announcement signal v(k) for feedforward action.
the three controllers depending on the measured glucose level.
The scheduling thresholds are selected to be 80 and 160 mg/dL,
since the controller aims at maintaining normoglycemia, avoid
reaching hypoglycemia, and reduce the elevated hyperglycemic
peaks. The MPC receives the scheduling signal, the meal an-
nouncement, the reference glucose level r(k), and the CGM
readings. The pump receives the controller signal and deliver it
as basal and/or bolus insulin.
IV. RESULTS
The UVa simulator is equipped with many numerical and
graphical metrics that can be used to evaluate the performance
of the control algorithms. Among these, the primary metrics
are: percentage of time within (70–180) mg/dL range, low BG
risk index (LBGI) or the hypoglycemic risk, and the “control
variability grid analysis” (CVGA); for more details about these
metrics and others, see [12] and [13].
A. Scenario Setup
Through the development of the controller, various scenar-
ios have been simulated to study the main factors affecting
the controller performance, including: the performance of feed-
forward control against meal disturbances (see Section IV-B1),
controller ability to handle the erroneous estimation of carbohy-
drates’ (CHO’s) amount in meal (see Section IV-B2), superiority
of GS-MPC over conventional MPC in dealing with interpa-
tients variability (see Section IV-B3), and the benefit of con-
troller’s individualization for each patient (see Section IV-B4).
Also, good set-point tracking and avoidance of overnight hypo-
glycemia have been taken into consideration in all scenarios.
Meal protocols that have been used in clinical and in silico
trials are available in literature (see [6] and [10]). In our work,
the simulation scenarios consider a three-day testing period, in
which meal sizes and times are not restrictedly fixed, to account
for patient real life where adherence to a fixed rule in meals’ size
and timing is difficult to achieve. The meals used in simulation
are given in Table I.
The set point r(k) for BG is selected to be 120 mg/dL since
the glycemic target for T1DM patients at fasting conditions is
about 100 mg/dL and the 2-h postprandial glucose level to be
lower than 140 mg/dL, and the constant mean value 120 mg/dL
has been selected. The set point 120 mg/dL is frequently used
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TABLE I
DAILY CHOs AMOUNT
in clinical trials (see [5] and [6]). To start the in silico testing,
the controller has been plugged into the simulator, so that the
controller receives the signals, as in Fig. 1, and delivers the
calculated insulin dose to the insulin pump.
During the tuning of the controller’s parameters, the follow-
ing have been considered, the prediction horizon Hp is estab-
lished since about 3 h are taken for the BG to return to steady
state after a meal. A prediction horizon of 4 h is mainly used
to consider the effect of insulin for 1 h more (i.e., to be more
conservative in insulin dosing) and avoid hypoglycemic event
that might result after a big meal. The 4-h (i.e., 48 sampling in-
terval) horizon might result in a slightly higher hyperglycemic
peaks, but it showed to be better than 3 h in dealing with hy-
poglycemic risk that is more life-threatening; for Hu, a length
of 1 sampling interval (5 min) is tested and considered be suf-
ficient. For ymin and ymax , the values have been selected to
constrain the BG levels within the normoglycemic range (70–
180 mg/dL) and keep a safety margin, and therefore, the (110–
160 mg/dL) set has been used for most patients. The values
for Vmin/Vmax have been selected in such a manner to penal-
ize hypoglycemia more aggressively than hyperglycemia, and
avoid infeasibility in optimization that could result from hard
constraints. The Vmin/Vmax is a key tuning parameter that can
be increased or decreased depending on patient’s dynamics and
sensitivity (e.g., smaller Vmin/Vmax for patients with higher risk
of hypoglycemia). The weights wy and w∆u have been selected
such that the reference tracking (BG closed to set point) has a
larger priority than the change in the insulin input during the
optimization. Finally, for the input constraints umax , umin , and
∆u, the values have been selected so that they remain within
the maximum allowable values for patient’s safety, and achieve
the pump hardware specification and limitations. The controller
parameters used in Section IV-B1–B3 are: Hp = 48, Hu = 1,
wy = 1, w∆u = 0.001, q = 105 , Vmin/Vmax = 0.0001/0.01,
ymin = 110 mg/dL, ymax = 160 mg/dL, umin = 0 U/h, umax =
70 U/h, and |∆u|max = 0.9umax = 63 U/h. Some of these pa-
rameters (mainlyHp , Vmin/Vmax , and ymin and ymax ) have been
subjected to further tuning in Section IV-B4 and B5 scenarios
to achieve better individualized control for some patients.
In the scenarios 1–3 in Section IV-B, a general controller
configuration has been used in the simulation; the models incor-
porated in the MPC are the three linearized models of an average
patient (patient that has the average values of the ten adults pa-
rameters), and the controller tuning parameters have not been
modified for each patient, but adjusted to achieve good perfor-
mance for the whole group. Conversely, in the scenarios in 4 and
5, while the same average models are used, individual controller
tuning has been performed for each patient separately, depend-
ing on each patient’s characteristics, ten tuning procedures have
Fig. 2. (Top) Adult 5 BG trace with (solid) and without (dashed) feedforward
loop. (Middle) Insulin infusion with (solid) and without (dashed) feedforward
loop. (Bottom) Feedforward insulin bolus.
been performed for the ten adults to explore the possibility of
further performance improvement.
B. Discussion
1) Feedforward Loop: To study the effectiveness of the feed-
forward action, two simulations have been performed with and
without the feedforward loop. When feedforward loop is im-
plemented, as in Fig. 1, the controller is announced about the
upcoming meal, and the value of the meal is included in the
prediction of future values of BG [see vk in (1)], and conse-
quently, the meal effect on BG will be considered in calculating
the future insulin dose.
While in the feedback-alone scenario, the vk value is always
zero and the meal effect is not considered in the prediction, and
therefore, the insulin infusion is depending on the CGM feed-
back signal and the MPC predictions. Thus, the meal correction
only starts after the meal effect appears in the CGM readings.
Fig. 2 shows that the controller performs well in both con-
figurations; however, it can be noticed that better results have
been obtained with the feedforward loop: less fluctuations in BG
levels (narrower range of BG readings), better set point tracking
(mean BG is closer to 120 mg/dL), and lower hyperglycemic
peaks, since the feedforward starts to deliver insulin before the
meals effect appears in the CGM feedback loop. Also, it should
be noticed that the feedforward is used to activate the pump bolus
feature, while in the feedback-alone scenario, the insulin infu-
sion makes use of the pump basal only. Feedforward loop has
been tested with the ten adults, and proved to give better results
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Fig. 3. Adult 5 BG trace with nominal meal (solid), meal 25% overestimation
errors (dashed), and underestimation errors (dotted).
than feedback-alone configuration; therefore, feedforward has
been implemented in all the following scenarios.
2) Meal Estimation Error: Whereas meal announcement
(informing the controller about the upcoming meal) is essen-
tial for good feedforward compensation, it is not uncommon
that the estimation for CHO content of the meal be incorrect,
or that the calculated value is not totally delivered into blood
stream. Therefore, a feedforward controller should have a good
level of robustness against both meal over- and under estimation
errors. The controller has been tested against over- and under-
estimation errors up to 25%. Fig. 3 shows the glucose levels
obtained for one patient (adult 5) with the 25% errors. For the
three scenarios (nominal meal, and overestimation errors, and
underestimation errors), the controller has been able to keep the
BG level within the safe range of normoglycemia. It was sur-
prising that for all patients, the controller response has not been
affected by small and moderate estimation errors, while only
minimum performance degradation has been noticed with 25%
errors.
3) GS-MPC Versus MPC: To study the feasibility of the
GS-MPC and its advantage over the conventional MPC, both
controllers have been tested with the ten adults’ population.
While the MPC uses a single linear average model of the ten
adults, the GS-MPC consists of three controllers, each of them
contains one of the three average models that have been extracted
in the hyper-, hypo-, and normoglycemic ranges. The GS is
used to select between these three controllers in function of the
glucose level provided by CGM. The CVGA tool developed in
[12] is provided in the simulator as a tool to evaluate the control
algorithm with the whole population. For the controller to be
considered as “working good” or providing “optimal control,” it
should keep the patients within the A and B zones of the CVGA.
Fig. 4 shows the CVGA for the results obtained by the two
controllers with ten adults during three days period (30 points,
each represents the BG min/max pair obtained for one patient
during one day). As the figure indicates, the GS-MPC has a
superior performance over the conventional MPC, especially
with those patients who exhibit higher nonlinear behavior and
higher insulin sensitivity. It can be seen that by using the GS,
the controller can handle each region separately and provide
better control than the conventional MPC that controls the whole
glycemic range with a single linear model. The MPC with GS
is able to keep all the patients within the A and B zones. None
of the patients is within the D and F dangerous zones.
Fig. 4. CGVA for ten adults’ population. (left) With GS-MPC. (Right) With
conventional linear MPC. Each dot represents one subject during one day of the
simulation period.
Numerical metrics available in the simulator, such as: percent-
age within 70–180 mg/dL range, percentage below 50 mg/dL,
percentage above 280 mg/dL, LBGI and high BG risk index
(HBGI), total risk index, and BG means, have been used to
get a detailed idea about the GS-MPC controller performance.
Table II demonstrates the obtained numerical results. It can be
seen from the table that tight control has been achieved for all
patients. None of the patient reaches the hypoglycemic range
(below 70 mg/dL), none of them reaches severe hyperglycemia
(above 280 mg/dL), and the risk indexes show that all patients
are within the safe range of glycemia (e.g., the LBGI is below
the 2.5 limits of “low-risk” range) [13], [28].
4) Individual Controller: In the previous scenarios, a gen-
eral controller configuration has been tested, i.e., the controller
incorporates the models of an “average patient” and the tuning
parameters have not been modified between patients, and good
performance has been verified. However, since a wide range of
interpatients variability can be observed among diabetic popu-
lation, it is obvious that a general configuration controller tuned
for the whole population will not be as good as an individual
controller that is tuned for each patient separately. To explore
the possibility of further controller improvement, individual tun-
ing (mainly for Hp , Vmin/Vmax , and ymin and ymax ) has been
performed for each patient separately. The tuning procedure is
performed by using patients’ parameters that can be obtained in
clinical tests, such as: the CHO–insulin ration (CR) that gives
the insulin units needed to eliminate the effect of certain amount
of CHO grams, the correction factor (CF) that represents the in-
sulin units needed to drop the BG by a certain number of points
(in milligrams per deciliter), the patients’ fasting BG, and the
patients’ body weights (BWs). These parameters and others are
available in the UVa simulator.
The obtained results in Table III emphasize the fact that the
good performance in the previous scenario can be further im-
proved by individual tuning. The population stays within the
acceptable range of 70–180 mg/dL for 99.7% of the three-days
period, the fluctuation in BG is minimized (narrower range be-
tween pre- and postmeal BG means), lower risk indexes have
been achieved for all patients, and insulin overdosing problem
has not occurred (no postprandial hypoglycemic events) despite
of the realistic meals’ values that have been used in the testing
scenarios.
5) In Silico Validation: Although the good performance ob-
tained in the previous sections indicates that the GS-MPC
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TABLE II
RESULTS FROM CONTROLLER TESTING WITH ADULTS’ POPULATION (GS-MPC CONTROLLER TUNED FOR THE WHOLE GROUP)
TABLE III
RESULTS FROM GS-MPC CONTROLLER TESTING WITH ADULTS’ POPULATION, INDIVIDUAL CONTROLLER TUNING
Fig. 5. Controller in silico validation: comparison between the performance
of the designed controller with one of the UVa patients (adult 6) and one of the
patients reported [21] (patient 2).
approach can nicely work and is applicable to the BG con-
trol problem, a validation could be done in silico by testing
the controller performance against unknown dynamic model of
the glucose–insulin system. For this purpose, the GS-MPC has
been tested with the model developed by Hovorka et al. [21].
It is another nonlinear glucose–insulin model with a structure
different from the one developed by Dalla Man and used in the
UVa simulator.
Fig. 5 shows a comparison between two BG profiles ob-
tained for one of the adults in the UVa simulator (adult 6), and
one of the patients reported in [21] (patient 2). It can be seen
that good control has been achieved for the hovorka patient al-
though it is represented by a model that is totally different from
the one implemented in the GS-MPC and used in the controller
design. While satisfactory results could be achieved with the
GS-MPC general configuration, the results in Fig. 5 have been
obtained by considering the Hovorka patient as any other patient
in the UVa simulator who needs individual tuning; therefore,
the output constraints have been relaxed to 90/160 mg/dL for
both patients. The figure also shows that two patients reach the
120 mg/dL value after the meals’ disturbance is eliminated, even
with the presence of the sensor errors. When applying the de-
signed controller to another model, one should be careful about
the specific units used for BG (e.g., in milligrams per deciliter
or millimols per liter) and insulin input (e.g., in picomols per
minute per kilogram or milliunits per minute) in each model.
The results shown in Tables II and III for general and indi-
vidual tuning indicate that the total and premeal means of BG
(not the sensor readings) are very close to the target value of
120 mg/dL in the presence of large sensor errors (e.g., about
30 mg/dL of deviation from real BG).
It should be mentioned that in all scenarios, the controller is
initialized with an average basal insulin infusion required for the
average patient (average of ten adults) to establish a 120 mg/dL
fasting conditions, and since the set-point tracking has a larger
priority on the insulin input, the initialization of GS-MPC with
a value different from the one that is required for each patient
will only be noticed in the first period of starting the control,
because the MPC will establish a new basal depending on each
patient.
Although the simulation studies demonstrate a good con-
troller performance, additional points should be considered be-
fore moving the controller into clinical use where real conditions
defer from those that can be generated in simulation environ-
ments. For instance, for night periods, where the risk of low BG
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readings increases, increased set-point value (e.g., 140 mg/dL)
can be used in attempt to reduce the insulin infusion, and con-
sequently, the risk of hypoglycemia. Another action that can be
considered is an alarm system that is activated when low BG
level (e.g, <80 mg/dL) is detected. The alarm system can be
used to give a warning sign for rapid intervention.
V. CONCLUSION
In this paper, a feedback–feedforward MPC controller with
GS has been developed for BG closed-loop control problem.
The applicability and the performance of the proposed con-
trol scheme have been evaluated in silico. The prediction abil-
ity of the MPC, enforced by effects of GSC and asymmetric
cost function, resulted in a good controller performance and
“adaptation” to different glucose ranges such that neither hypo-
glycemic events nor elevated hyperglycemia has been observed
during simulation, although big-size meals have been used. A
good level of robustness against meal over- and under estima-
tion has been demonstrated. Also, the controller has shown good
performance against interpatients variability and model–patient
mismatch. In addition, while the GS-MPC has been driven by
the CGM that can produce measurements errors up to 30 mg/dL,
the controller has been able to nicely reject the sensor errors ef-
fects. In order to validate the controller that has been developed,
the model used in the controller design was not the same model
that is used in the validation.
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